Glasdegib plus intensive/nonintensive chemotherapy in untreated acute myeloid leukemia: BRIGHT AML 1019 Phase III trials

Phase 1/2 trial of glasdegib in patients with primary or secondary myelofibrosis previously treated with ruxolitinib

(2019) Aaron T. Gerds et al.   LEUKEMIA RESEARCH

Phase Ib Study of Glasdegib, a Hedgehog Pathway Inhibitor, in Combination with Standard Chemotherapy in Patients with AML or High-Risk MDS

(2018) Michael R. Savona et al.   CLINICAL CANCER RESEARCH

Global, Regional, and National Cancer Incidence, Mortality, Years of Life Lost, Years Lived With Disability, and Disability-Adjusted Life-Years for 29 Cancer Groups, 1990 to 2016

(2018) et al.   JAMA Oncology

Glasdegib in combination with cytarabine and daunorubicin in patients with AML or high-risk MDS: Phase 2 study results

(2018) Jorge E. Cortes et al.   AMERICAN JOURNAL OF HEMATOLOGY

Acute myeloid leukaemia

(2018) Nicholas J Short et al.   LANCET

Randomized comparison of low dose cytarabine with or without glasdegib in patients with newly diagnosed acute myeloid leukemia or high-risk myelodysplastic syndrome

(2018) Jorge E. Cortes et al.   LEUKEMIA

NANOG Expression as a Responsive Biomarker during Treatment with Hedgehog Signal Inhibitor in Acute Myeloid Leukemia

(2017) Seiji Kakiuchi et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

Understanding of leukemic stem cells and their clinical implications

(2017) Xuefei Wang et al.   Molecular Cancer

Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel

(2016) Hartmut Döhner et al.   BLOOD

The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia

(2016) D. A. Arber et al.   BLOOD

Small-molecule Hedgehog inhibitor attenuates the leukemia-initiation potential of acute myeloid leukemia cells

(2016) Nobuaki Fukushima et al.   CANCER SCIENCE

NIH Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: II. The 2014 Pathology Working Group Report

(2015) Howard M. Shulman et al.   BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION

National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: I. The 2014 Diagnosis and Staging Working Group Report

(2015) Madan H. Jagasia et al.   BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION

International phase 3 study of azacitidine vs conventional care regimens in older patients with newly diagnosed AML with >30% blasts

(2015) H. Dombret et al.   BLOOD

Targeting of the Hedgehog pathway in myeloid malignancies: still a worthy chase?

(2015) Alesia A. Khan et al.   BRITISH JOURNAL OF HAEMATOLOGY

The Hedgehog pathway as targetable vulnerability with 5-azacytidine in myelodysplastic syndrome and acute myeloid leukemia

(2015) Raoul Tibes et al.   Journal of Hematology & Oncology

GLI2 inhibition abrogates human leukemia stem cell dormancy

(2015) Anil Sadarangani et al.   Journal of Translational Medicine

Treatment with PF-04449913, an oral smoothened antagonist, in patients with myeloid malignancies: a phase 1 safety and pharmacokinetics study

(2015) Giovanni Martinelli et al.   Lancet Haematology

A Phase I Study of PF-04449913, an Oral Hedgehog Inhibitor, in Patients with Advanced Solid Tumors

(2014) A. J. Wagner et al.   CLINICAL CANCER RESEARCH

Sense and nonsense of high-dose cytarabine for acute myeloid leukemia

(2013) B. Lowenberg   BLOOD

Incidence, survival and prevalence of myeloid malignancies in Europe

(2012) O. Visser et al.   EUROPEAN JOURNAL OF CANCER

Hedgehog pathway as a drug target: Smoothened inhibitors in development

(2012) Tara Lin et al.   OncoTargets and Therapy

Long-Term Prognosis of Acute Myeloid Leukemia According to the New Genetic Risk Classification of the European LeukemiaNet Recommendations: Evaluation of the Proposed Reporting System

(2011) Christoph Röllig et al.   JOURNAL OF CLINICAL ONCOLOGY

Hedgehog signaling maintains chemoresistance in myeloid leukemic cells

(2010) K C S Queiroz et al.   ONCOGENE

Anthracycline Dose Intensification in Acute Myeloid Leukemia

(2009) Hugo F. Fernandez et al.   NEW ENGLAND JOURNAL OF MEDICINE

High-Dose Daunorubicin in Older Patients with Acute Myeloid Leukemia

(2009) Bob Löwenberg et al.   NEW ENGLAND JOURNAL OF MEDICINE